# US 2020/0369781 A1 · Polypeptide including antigen-binding domain and carrying section

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369781 A1
- Document ID: US20200369781A1
- Status: Published application
- Kind: A1
- Application number: 16/767,085
- Filed: 2018-11-28
- Published: 2020-11-26
- Earliest claimed: 2017-11-28
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Tomoyuki IGAWA; Hiroyuki ISHIKAWA; Naoka HIRONIWA; Tatsuya KAWA
- Web page: https://patentgrep.com/patent/US20200369781A1

## CPC

- C07K 16/303: {Liver or Pancreas}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/005: {constructed by phage libraries}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/32: against translation products of oncogenes
- C07K 16/4208: {against an idiotypic determinant on Ig}
- C07K 16/4241: {against anti-human or anti-animal Ig}
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/31: multispecific
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to polypeptides containing an antigen-binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen-binding activity of the antigen-binding domain, and having a longer half-life than that of the antigen-binding domain existing alone; methods for producing and screening for the polypeptides; pharmaceutical compositions containing the polypeptide; methods for producing and screening for a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH; and fusion polypeptide libraries including a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH.

## Claims

### Claim 1

A polypeptide comprising an antigen-binding domain and a carrying moiety, wherein the carrying moiety has an inhibiting domain that inhibits the antigen-binding activity of the antigen-binding domain, and wherein the polypeptide has a protease cleavage sequence comprising one or a plurality of sequences selected from the sequences of SEQ ID NOs: 833 to 852 and SEQ ID NOs: 1062 to 1081 and the sequences described in Table 1.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein inhibition of antigen-binding activity of the antigen-binding domain by the inhibiting domain in a state where the protease cleavage sequence has been cleaved by a protease is weaker than the inhibition of antigen-binding activity of the antigen-binding domain by the inhibiting domain in a state where the protease cleavage sequence is uncleaved.

### Claim 3 (depends on 1, 2)

The polypeptide of claim 1 or 2, wherein the antigen-binding domain has a shorter half-life in blood than the carrying moiety.

### Claim 4 (depends on 1, 2, 3)

The polypeptide of any one of claims 1 to 3, wherein the antigen-binding domain is capable of being released from the polypeptide, and wherein the antigen-binding domain has higher antigen-binding activity in a state where it is released from the polypeptide than antigen-binding activity in a state where it is not released from the polypeptide.

### Claim 5 (depends on 1, 2, 3, 4)

The polypeptide of any one of claims 1 to 4, wherein the antigen-binding activity of the antigen-binding domain is inhibited by the association of the inhibiting domain of the carrying moiety with the antigen-binding domain.

### Claim 6 (depends on 4, 5)

The polypeptide of claim 4 or 5, wherein the protease cleavage sequence is cleaved by a protease, so that the antigen-binding domain becomes capable of being released from the polypeptide or/and so that the association of the inhibiting domain of the carrying moiety with the antigen-binding domain is canceled.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The polypeptide of any one of claims 1 to 6, wherein the protease is a cancer tissue specific protease or an inflammatory tissue specific protease.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The polypeptide of anyone of claims 1 to 7, wherein the antigen-binding domain comprises a single-domain antibody or is a single-domain antibody, and wherein the inhibiting domain of the carrying moiety inhibits the antigen-binding activity of the single-domain antibody.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The polypeptide of anyone of claims 1 to 8, wherein the antigen-binding domain comprises a single-domain antibody, wherein the inhibiting domain of the carrying moiety is a VHH, an antibody VH, or an antibody VL, and wherein the antigen-binding activity of the single-domain antibody is inhibited by the VHH, the antibody VH, or the antibody VL.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The polypeptide of any one of claims 1 to 9, wherein the carrying moiety comprises an antibody constant region.

### Claim 11 (depends on 10)

The polypeptide of claim 10, wherein the N terminus of the antibody constant region of the carrying moiety and the C terminus of the antigen-binding domain are fused via a linker or without a linker, and wherein the protease cleavage sequence is located near the boundary between the antigen-binding domain and the antibody constant region.

### Claim 12 (depends on 10, 11)

The polypeptide of claim 10 or 11, wherein the antibody constant region of the polypeptide is an IgG antibody constant region.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The polypeptide of any one of claims 1 to 12, wherein the polypeptide is an IgG antibody-like molecule.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising the polypeptide of anyone of claims 1 to 13.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method for producing the polypeptide of any one of claims 1 to 13.
